drugset / Trial / NCT00289809

TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients

NCT00289809

Phase 1/2 Completed 36 enrolled Istituto Clinico Humanitas
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined with ifosfamide and then the efficacy of this combination in terms of overall response rate, time to progression and time of response

Timeline

Start
2006-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 40 mg/m2
Subject Ifosfamide Small molecule 3000 mg/m2

Indications